Advances in HIV-1 Vaccine Development

Yong Gao; Paul F McKay; Jamie F S Mann

doi:10.3390/v10040167

Advances in HIV-1 Vaccine Development

Yong Gao, Paul F McKay, Jamie F S Mann

Research output: Contribution to journal › Review article (Academic Journal) › peer-review

55 Citations (Scopus)

Abstract

An efficacious HIV-1 vaccine is regarded as the best way to halt the ongoing HIV-1 epidemic. However, despite significant efforts to develop a safe and effective vaccine, the modestly protective RV144 trial remains the only efficacy trial to provide some level of protection against HIV-1 acquisition. This review will outline the history of HIV vaccine development, novel technologies being applied to HIV vaccinology and immunogen design, as well as the studies that are ongoing to advance our understanding of vaccine-induced immune correlates of protection.

Original language	English
Journal	Viruses
Volume	10
Issue number	4
DOIs	https://doi.org/10.3390/v10040167
Publication status	Published - 1 Apr 2018

Keywords

AIDS Vaccines/administration & dosage
Animals
Antibodies, Neutralizing/blood
Clinical Trials as Topic
Drug Evaluation, Preclinical
HIV Antibodies/blood
HIV Infections/prevention & control
HIV-1/genetics
Host-Pathogen Interactions/immunology
Humans
Immunogenicity, Vaccine
Outcome Assessment, Health Care
Structure-Activity Relationship
Vaccination
Viral Proteins/chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/v10040167

Handle.net

Persistent link

Cite this

@article{627db4d18e684855b27ae7e16b123e52,

title = "Advances in HIV-1 Vaccine Development",

abstract = "An efficacious HIV-1 vaccine is regarded as the best way to halt the ongoing HIV-1 epidemic. However, despite significant efforts to develop a safe and effective vaccine, the modestly protective RV144 trial remains the only efficacy trial to provide some level of protection against HIV-1 acquisition. This review will outline the history of HIV vaccine development, novel technologies being applied to HIV vaccinology and immunogen design, as well as the studies that are ongoing to advance our understanding of vaccine-induced immune correlates of protection.",

keywords = "AIDS Vaccines/administration & dosage, Animals, Antibodies, Neutralizing/blood, Clinical Trials as Topic, Drug Evaluation, Preclinical, HIV Antibodies/blood, HIV Infections/prevention & control, HIV-1/genetics, Host-Pathogen Interactions/immunology, Humans, Immunogenicity, Vaccine, Outcome Assessment, Health Care, Structure-Activity Relationship, Vaccination, Viral Proteins/chemistry",

author = "Yong Gao and McKay, {Paul F} and Mann, {Jamie F S}",

year = "2018",

month = apr,

day = "1",

doi = "10.3390/v10040167",

language = "English",

volume = "10",

journal = "Viruses",

issn = "1999-4915",

publisher = "MDPI AG",

number = "4",

}

TY - JOUR

T1 - Advances in HIV-1 Vaccine Development

AU - Gao, Yong

AU - McKay, Paul F

AU - Mann, Jamie F S

PY - 2018/4/1

Y1 - 2018/4/1

N2 - An efficacious HIV-1 vaccine is regarded as the best way to halt the ongoing HIV-1 epidemic. However, despite significant efforts to develop a safe and effective vaccine, the modestly protective RV144 trial remains the only efficacy trial to provide some level of protection against HIV-1 acquisition. This review will outline the history of HIV vaccine development, novel technologies being applied to HIV vaccinology and immunogen design, as well as the studies that are ongoing to advance our understanding of vaccine-induced immune correlates of protection.

AB - An efficacious HIV-1 vaccine is regarded as the best way to halt the ongoing HIV-1 epidemic. However, despite significant efforts to develop a safe and effective vaccine, the modestly protective RV144 trial remains the only efficacy trial to provide some level of protection against HIV-1 acquisition. This review will outline the history of HIV vaccine development, novel technologies being applied to HIV vaccinology and immunogen design, as well as the studies that are ongoing to advance our understanding of vaccine-induced immune correlates of protection.

KW - AIDS Vaccines/administration & dosage

KW - Animals

KW - Antibodies, Neutralizing/blood

KW - Clinical Trials as Topic

KW - Drug Evaluation, Preclinical

KW - HIV Antibodies/blood

KW - HIV Infections/prevention & control

KW - HIV-1/genetics

KW - Host-Pathogen Interactions/immunology

KW - Humans

KW - Immunogenicity, Vaccine

KW - Outcome Assessment, Health Care

KW - Structure-Activity Relationship

KW - Vaccination

KW - Viral Proteins/chemistry

U2 - 10.3390/v10040167

DO - 10.3390/v10040167

M3 - Review article (Academic Journal)

C2 - 29614779

SN - 1999-4915

VL - 10

JO - Viruses

JF - Viruses

IS - 4

ER -

Advances in HIV-1 Vaccine Development

Abstract

Keywords

UN SDGs

Access to Document

Handle.net

Fingerprint

Cite this